These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19771540)

  • 1. The application of bespoke spending functions in group-sequential designs and the effect of delayed treatment switching in survival trials.
    Stone A
    Pharm Stat; 2010; 9(2):151-61. PubMed ID: 19771540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
    Lachin JM
    Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction of group sequential designs in clinical trials on the basis of detectable treatment differences.
    Schäfer H; Müller HH
    Stat Med; 2004 May; 23(9):1413-24. PubMed ID: 15116350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Group sequential designs for monitoring survival probabilities.
    Lin DY; Shen L; Ying Z; Breslow NE
    Biometrics; 1996 Sep; 52(3):1033-41. PubMed ID: 8805766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient group sequential designs when there are several effect sizes under consideration.
    Jennison C; Turnbull BW
    Stat Med; 2006 Mar; 25(6):917-32. PubMed ID: 16220524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A practical comparison of group-sequential and adaptive designs.
    Kelly PJ; Sooriyarachchi MR; Stallard N; Todd S
    J Biopharm Stat; 2005; 15(4):719-38. PubMed ID: 16022175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Just Another Statistic".
    Machtay M; Glatstein E
    Oncologist; 1998; 3(3):III-IV. PubMed ID: 10388105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-designing trial combined with classical group sequential monitoring.
    Yin G; Shen Y
    J Biopharm Stat; 2005; 15(4):667-75. PubMed ID: 16022171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stopping clinical trials early for benefit: impact on estimation.
    Freidlin B; Korn EL
    Clin Trials; 2009 Apr; 6(2):119-25. PubMed ID: 19342463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
    Zhao Y; Grambsch PM; Neaton JD
    Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal spending functions for asymmetric group sequential designs.
    Anderson KM
    Biom J; 2007 Jun; 49(3):337-45. PubMed ID: 17623339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and analysis of group sequential logrank tests in maximum duration versus information trials.
    Kim K; Boucher H; Tsiatis AA
    Biometrics; 1995 Sep; 51(3):988-1000. PubMed ID: 7548714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials.
    Hung HM; Wang SJ; O'Neill R
    J Biopharm Stat; 2007; 17(6):1201-10. PubMed ID: 18027226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementing type I & type II error spending for two-sided group sequential designs.
    Rudser KD; Emerson SS
    Contemp Clin Trials; 2008 May; 29(3):351-8. PubMed ID: 17933592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of group sequential logrank tests in a maximum duration trial.
    Lan KK; Lachin JM
    Biometrics; 1990 Sep; 46(3):759-70. PubMed ID: 2242413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?
    Amir E; Seruga B; Kwong R; Tannock IF; Ocaña A
    Eur J Cancer; 2012 Feb; 48(3):385-8. PubMed ID: 22115991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal two-stage designs for clinical trials based on safety and efficacy.
    Thall PF; Cheng SC
    Stat Med; 2001 Apr; 20(7):1023-32. PubMed ID: 11276033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spending functions and continuous-monitoring boundaries.
    Proschan MA; Lan KK
    Stat Med; 2012 Nov; 31(25):3024-30. PubMed ID: 22807204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flexible stopping boundaries when changing primary endpoints after unblinded interim analyses.
    Chen LM; Ibrahim JG; Chu H
    J Biopharm Stat; 2014; 24(4):817-33. PubMed ID: 24697500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.